デフォルト表紙
市場調査レポート
商品コード
1212665

免疫グロブリン製剤(IVIg)静注用の世界市場

Intravenous Immunoglobulin (IVIg)

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 184 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=150.28円
免疫グロブリン製剤(IVIg)静注用の世界市場
出版日: 2023年01月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 184 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

免疫グロブリン製剤(IVIg)静注用の世界市場は2030年に306億米ドルに達する

変化したCOVID-19後のビジネス環境において、2022年に156億米ドルと推定される免疫グロブリン製剤(IVIg)静注用の世界市場は、2030年までに306億米ドルの改定規模に達し、分析期間2022-2030年に8.8%のCAGRで成長すると予測されます。本レポートで分析したセグメントの1つであるIgAは、CAGR10.8%を記録し、分析期間終了時には125億米ドルに達すると予測されます。パンデミック後の回復を考慮し、IgE分野の成長は次の8年間のCAGRが7.9%に修正されます。

米国市場は46億米ドル、中国はCAGR8.1%で成長すると予測される

米国の免疫グロブリン製剤(IVIg)静注用市場は、2022年には46億米ドルになると推定されます。世界第2位の経済大国である中国は、2022年から2030年にかけてのCAGRが8.1%で、2030年には52億米ドルの市場規模に達すると予測されています。その他の注目すべき地域市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ7.9%と7.1%の成長が予測されています。欧州では、ドイツがCAGR約6.5%で成長すると予測されています。

調査対象企業の例

  • Bharat Serums and Vaccines Limited
  • Biotest AG
  • China Biologic Products, Inc.
  • CSL Limited
  • Grifols, S.A.
  • Hualan Biological Engineering Inc.
  • Kedrion S.p.A.
  • LFB Group
  • Octapharma AG
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shire plc
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP-7776

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Intravenous Immunoglobulin (IVIg) Market to Reach $30.6 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Intravenous Immunoglobulin (IVIg) estimated at US$15.6 Billion in the year 2022, is projected to reach a revised size of US$30.6 Billion by 2030, growing at a CAGR of 8.8% over the analysis period 2022-2030. IgA, one of the segments analyzed in the report, is projected to record a 10.8% CAGR and reach US$12.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the IgE segment is readjusted to a revised 7.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $4.6 Billion, While China is Forecast to Grow at 8.1% CAGR

The Intravenous Immunoglobulin (IVIg) market in the U.S. is estimated at US$4.6 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.2 Billion by the year 2030 trailing a CAGR of 8.1% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.9% and 7.1% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Select Competitors (Total 24 Featured):

  • Bharat Serums and Vaccines Limited
  • Biotest AG
  • China Biologic Products, Inc.
  • CSL Limited
  • Grifols, S.A.
  • Hualan Biological Engineering Inc.
  • Kedrion S.p.A.
  • LFB Group
  • Octapharma AG
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shire plc
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Intravenous Immunoglobulin (IVIg) - Global Key Competitors Percentage Market Share in 2023 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2023 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Intravenous Immunoglobulin (IVIg) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Intravenous Immunoglobulin (IVIg) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 4: World 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for IgA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 6: World Historic Review for IgA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 7: World 16-Year Perspective for IgA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for IgE by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 9: World Historic Review for IgE by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 10: World 16-Year Perspective for IgE by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for IgG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 12: World Historic Review for IgG by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 13: World 16-Year Perspective for IgG by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for IgM by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 15: World Historic Review for IgM by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 16: World 16-Year Perspective for IgM by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for IgD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 18: World Historic Review for IgD by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 19: World 16-Year Perspective for IgD by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 25: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Homecare Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Homecare Settings by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 28: World 16-Year Perspective for Homecare Settings by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
  • JAPAN
    • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
  • CHINA
    • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 49: China 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 52: China 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
  • EUROPE
    • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Intravenous Immunoglobulin (IVIg) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
  • FRANCE
    • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 64: France 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 67: France 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
  • GERMANY
    • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 88: Rest of Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Intravenous Immunoglobulin (IVIg) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 94: Asia-Pacific 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Intravenous Immunoglobulin (IVIg) by Type - IgA, IgE, IgG, IgM and IgD Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 100: Rest of World 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by Type - Percentage Breakdown of Value Sales for IgA, IgE, IgG, IgM and IgD for the Years 2014, 2023 & 2030
    • TABLE 101: Rest of World Recent Past, Current & Future Analysis for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
    • TABLE 102: Rest of World Historic Review for Intravenous Immunoglobulin (IVIg) by End-Use - Hospitals, Clinics and Homecare Settings Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
    • TABLE 103: Rest of World 16-Year Perspective for Intravenous Immunoglobulin (IVIg) by End-Use - Percentage Breakdown of Value Sales for Hospitals, Clinics and Homecare Settings for the Years 2014, 2023 & 2030

IV. COMPETITION